The restructuring of Minnesota’s newest large public company announced in December will result in $120 million in annual savings.

During Q4 2024, Solventum experienced varied performance across its segments. The MedSurg segment saw organic sales growth of 1.8%, boosted by product strategies like negative pressure wound therapy.

Currently, McMillan serves as CFO at Solventum, the 3M Health Care spinoff. He officially became Solventum’s CFO after its ...

Formerly 3 M’s (NYSE:MMM) Health Care Business, Solventum, started trading as a newly independent healthcare company in April 2024. The company offers solutions for wound care, surgery ...

Solventum, the 3M healthcare spinoff, eliminated 800 positions as part of a restructuring strategy to help fuel growth. CEO Bryan Hanson, in an investor day presentation last week, said the ...

Solventum forecasts annual profit above estimates on strong surgical product sales 3M spin-off Solventum forecast annual profit above analyst estimates on Thursday, betting on strong sales of its ...

The company offers solutions for wound care, surgery, dental prevention, procedures, orthodontics, and software. “Solventum has tremendous potential, with attractive businesses, large and ...